Drugs / scAAV2-P1ND4v2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02161380 | Jul 2014 → Mar 2023 | Leber hereditary optic neuropathy | Byron Lam | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scAAV2-P1ND4v2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02161380 ↗ |
| Action | Restore | “scAAV2-P1ND4v2 (abbreviated as AAV-ND4) gene replacement therapy” NCT02161380 ↗ |
| Route | Intravitreal | “a single intravitreal injection” NCT02161380 ↗ |